Stockreport

Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pa...

Aptevo Therapeutics Inc.  (APVO) 
Last aptevo therapeutics inc. earnings: 8/9 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aptevotherapeutics.com/investor-overview
PDF Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously reported for FOLFIRINOX Furthe [Read more]